

1 **Unexpected Increase in Postoperative Atrial Fibrillation by Calcium-**  
2 **mediated Autonomic Denervation:**  
3 **Results of the CAP-AF2 Trial**

4 Huishan Wang, MD<sup>1\*</sup>; Yuji Zhang, MD<sup>1\*</sup>; Fangran Xin, PhD<sup>1</sup>; Jikai Zhao, MD<sup>1</sup>; Keyan Zhao,  
5 MD<sup>1</sup>; Dengshun Tao, MD<sup>1</sup>; Praloy Chakraborty, MD<sup>2</sup>; Zongtao Yin, MD<sup>1</sup>; Guannan Liu, MD<sup>1</sup>;  
6 Sunny S. Po, MD, PhD<sup>2</sup>

7 1. Department of Cardiovascular Surgery, General Hospital of Northern Theater Command,  
8 Shenyang, Liaoning, China

9 2. Section of Cardiovascular Diseases and Heart Rhythm Institute, University of Oklahoma  
10 Health Sciences Center, Oklahoma City, OK, USA

11 **\*: These authors contributed equally**

12

13 **Word Count:** 3815

14 **Short Title:** denervation increased postoperative atrial fibrillation

15 **Key Words:**

16 Autonomic nervous system, autonomic denervation, ganglionated plexi, postoperative atrial  
17 fibrillation,

18

19 **Corresponding Author:**

20 Sunny S. Po, MD, PhD

21 Section of Cardiovascular Diseases and Heart Rhythm Institute

22 University of Oklahoma Health Sciences Center

23 800 Stanton L. Young Blvd. Suite 5400, Oklahoma City, Oklahoma, USA

24 E-mail: [sunny-po@ouhsc.edu](mailto:sunny-po@ouhsc.edu) Telephone: 405-271-9696 Fax: 405-271-7455

25

26 **ABSTRACT**

27 **Background** In the CAP-AF trial, injection of calcium chloride (CaCl<sub>2</sub>) into the four major atrial  
28 ganglionated plexi (GP) reduced the relative risk of postoperative atrial fibrillation (POAF) by  
29 63% in patients undergoing coronary artery bypass surgery (CABG).

30 **Objective.** The CAP-AF2 trial intended to investigate if similar autonomic denervation could  
31 prevent POAF in patients with mitral regurgitation (MR) but without persistent AF who  
32 underwent surgery for MR.

33 **Methods** The CAP-AF-2 trial was an investigator-initiated, single center, double-blind,  
34 randomized clinical trial. This trial planned to 1:1 randomize 320 adult patients to CaCl<sub>2</sub> vs.  
35 sodium chloride (NaCl, sham) injection into the four GP during surgery. The primary outcome  
36 was incidence of POAF ( $\geq 30$  seconds) in 7 days. Secondary outcomes included length of  
37 hospitalization, POAF burden, actionable antiarrhythmic therapy for POAF, heart rate variability  
38 changes and plasma inflammatory markers.

39 **Results** This trial was terminated after midterm analysis showing that the cumulative POAF  
40 incidence was higher in the CaCl<sub>2</sub> group (43/78, 55.13%) than the NaCl group (31/82, 37.80%;  
41 confidence interval of difference 1.01%-32.48%,  $P= 0.028$ ). In the CaCl<sub>2</sub> group, more patients  
42 were hospitalized over 7 days (69.8% vs. 45.2%;  $p=0.033$ ) and more patients required  
43 amiodarone therapy ( $p=0.039$ ). AF burden, plasma inflammatory markers and heart rate  
44 variability were not different between the two groups. Frequent atrial bigeminy or nonsustained  
45 atrial tachycardia immediately preceded POAF in 76.7% (CaCl<sub>2</sub>) and 29.0% (NaCl) patients,  
46 respectively ( $P<0.001$ ), consistent with triggers caused by higher sympathetic activity.  
47 Immunohistochemistry study obtained from GP and left atrium during surgery revealed  
48 parasympathetic dominance in patients receiving MV surgery but sympathetic dominance in  
49 patients undergoing CABG.

50

51 **Conclusions** Unlike patients undergoing CABG, autonomic denervation increased the risk of  
52 POAF in patients receiving MR surgery, indicating distinct AF substrate in different  
53 cardiovascular diseases. Calcium-mediated autonomic denervation may have tipped the tissue  
54 autonomic balance toward sympathetic dominance and provided triggers for POAF. While  
55 autonomic denervation has emerged as a novel therapy to treat various cardiovascular diseases, it  
56 should only be performed with evidence supported by randomized clinical trials.

57 **The Chinese Clinical Trial Registry registration number:** ChiCTR2000029314.

58 **website:** <http://www.chictr.org.cn/showproj.aspx?proj=48587>

59

60 **CLINICAL PERSPECTIVES:**

61 **What is new:**

- 62 - Calcium-mediated autonomic denervation increased the incidence of post-operative  
63 atrial fibrillation (AF) in patient undergoing mitral valve surgery for severe mitral  
64 regurgitation, contradictory to the beneficial effects it exerted on patients undergoing  
65 coronary artery bypass surgery.

66 **Clinical implications:**

- 67 - Each cardiovascular disease may have its distinct autonomic balance at the tissue level.
- 68 - Mechanisms underlying the initiation and maintenance of AF vary greatly among  
69 cardiovascular diseases; autonomic denervation therefore can be beneficial or  
70 harmful.
- 71 - Autonomic denervation for each cardiovascular disease should only be performed with  
72 evidence from randomized clinical trials to demonstrate its efficacy and safety.

73

74

75

76 **Abbreviations:**

77 ANS: autonomic nervous system

78 CABG: coronary artery bypass grafting

79 CaCl<sub>2</sub>: calcium chloride

80 ChAT: choline acetyltransferase

81 GP: ganglionated plexi

82 MV: mitral valve

83 NaCl: sodium chloride

84 POAF: postoperative atrial fibrillation

85 TH: tyrosine hydroxylase

86

## 87 INTRODUCTION

88 Postoperative atrial fibrillation (POAF) is one of the most common complications of  
89 cardiac surgery and is a multifactorial disease.<sup>1,2</sup> Contributing factors include sympathetic surge,  
90 intense inflammation, oxidative stress and preexisting atrial diseases. Despite the use of  $\beta$ -  
91 blockers and amiodarone, the incidence of POAF remains high.<sup>3-5</sup>

92 Ganglionated plexi (GP), embedded in epicardial fat pads, are widely considered as the  
93 “integration centers” of the extensive neural network formed by the intrinsic cardiac autonomic  
94 nervous system (ANS).<sup>6-9</sup> GP contain both sympathetic and parasympathetic neural elements.  
95 Preclinical and clinical studies demonstrated that simultaneous or sequential activation of cardiac  
96 parasympathetic and sympathetic systems preceded AF initiation.<sup>10-12</sup> The four major atrial GP  
97 adjacent to pulmonary veins (PV) are particularly important in AF initiation and  
98 maintenance.<sup>13,14</sup> Circumferential PV isolation transects at least 3 of the 4 major atrial GP.  
99 Autonomic denervation therefore has been proposed to play an important role in the success of  
100 AF ablation.<sup>15,16</sup>

101 It is known that excessive intracellular  $\text{Ca}^{2+}$  concentration can be lethal to neurons.<sup>17,18</sup>  
102 In the CAP-AF (Calcium-mediated Autonomic Denervation in Postoperative Atrial Fibrillation)  
103 trial, we demonstrated that calcium-mediated neurotoxicity by injecting calcium chloride ( $\text{CaCl}_2$ )  
104 into the four major atrial GP reduced the incidence of POAF by 63% as compared to the sham  
105 injection sodium chloride (NaCl) in patients undergoing coronary artery bypass grafting surgery  
106 (CABG).<sup>19</sup> We hypothesized that the substrate of POAF and the role of ANS may be distinct  
107 among patients with different cardiovascular diseases. The CAP-AF2 trial was designed to  
108 investigate if Ca-mediated autonomic denervation could prevent POAF in patients with mitral  
109 regurgitation (MR) without persistent AF who underwent mitral valve (MV) replacement or  
110 repair.

## 111 **METHODS**

### 112 **Trial Design and oversight**

113 The Calcium-mediated Autonomic Denervation in Postoperative Atrial Fibrillation-2  
114 (CAP-AF2) trial is a single-center, sham-controlled, double-blind, randomized clinical trial that  
115 was conducted in accordance with the principles of the Declaration of Helsinki and the  
116 International Conference on Harmonization Good Clinical Practice Guideline. The protocol was  
117 approved by the Ethics Committee of the General Hospital of Northern Theater Command and  
118 registered in the Chinese Clinical Trial Registry (registration number: ChiCTR2000029314;  
119 website: <http://www.chictr.org.cn/showproj.aspx?proj=48587>). The trial was overseen by the Ethics  
120 Committee and the Science Discipline Department. Both committees had the authority to stop  
121 the trial for safety or efficacy concerns. All patients enrolled into this trial gave informed consent  
122 for participation.

123 The primary outcome is the incidence of POAF in the first 7 days after surgery.<sup>19</sup> POAF  
124 was defined as any atrial tachyarrhythmia episode<sup>5</sup> lasting  $\geq 30$  seconds following surgery.<sup>19</sup>  
125 Secondary outcomes include length of hospitalization following surgery, AF burden during the  
126 first 7 postoperative days, average ventricular rate during AF, percentage of patients with AF  
127 lasting  $\geq 24$  or 48 hours, actionable antiarrhythmic therapy to treat POAF, frequency of  
128 premature atrial contractions (PACs) as well as plasma level of inflammatory markers including  
129 interleukin-6 (IL-6) and high sensitivity c-reactive protein (hsCRP).

### 130 **Patient Population**

131 Adult patients referred for isolated MV repair or replacement for MR were eligible for  
132 enrollment. Exclusion criteria included: (1) adult patients  $>80$  years of age, (2) history of  
133 persistent AF or persistent AF detected by 7-day Holter monitoring before surgery, (3) prior  
134 cardiac surgery, 4) poor compliance or inability to complete follow-up, (5) urgent cardiac  
135 surgery, (6) congenital heart disease, (7) significant mitral stenosis (MV orifice area  $<2$  cm<sup>2</sup>), (8)

136 concomitant surgery of any kind, (9) abnormal liver or kidney function  $>3x$  upper normal limit,  
137 (10) diseases requiring radiotherapy, chemotherapy or long-term hormone treatment, (11)  
138 ejection fraction  $<40\%$ , (12) taking class I or III antiarrhythmic agents before surgery, (13)  
139 significant left atrial enlargement ( $>5$  cm), (14) concomitant AF ablation, (15) participating in  
140 another clinical trial and (16) refusal to enrollment.

#### 141 **Sample Size Calculation and Randomization**

142 We assumed a 40% incidence of POAF in the NaCl group based on the historical POAF  
143 incidence in the study center. We determined the enrollment of 152 CaCl<sub>2</sub> patients and 152  
144 NaCl patients would provide a power of at least 80% to detect a 15% absolute reduction in the  
145 incidence of POAF in the CaCl<sub>2</sub> group compared to the NaCl (sham) group with a two-sided  
146 type-I error rate of 0.05. We expected a 5% drop-out rate; each group will therefore require 160  
147 patients.

148 Eligible patients were randomly assigned to either the CaCl<sub>2</sub> group or NaCl group by  
149 means of a computer-generated randomization system with a block of 8 with the group  
150 assignment concealed. CaCl<sub>2</sub> or NaCl solution was prepared in a syringe accordingly. The  
151 surgery staff as well as the personnel involving post-operative care, clinical data collection and  
152 outcome assessment were blinded to randomization.

#### 153 **Preoperative baseline data collection**

154 Prior to surgery, all patients with severe MR referred for MV surgery received 7-day  
155 Holter monitoring with the capability of heart rate variability calculation.<sup>19</sup> Patients with a  
156 history of persistent AF or had AF for  $\geq 7$  days preoperatively were excluded from this study.  
157 The rest of the patients meeting the inclusion criteria were considered potential candidates.

#### 158 **Intervention**

159 After MV repair or replacement, operators performed multi-point injection of 2 mL of  
160 5% CaCl<sub>2</sub> or 0.9% NaCl into the four major atrial GP as previously described.<sup>19</sup> All the surgeons



161 were already familiar with the location of the four major atrial GP from the CAP-AF trial. The  
162 anterior right GP is located near the annular aspect of the right superior PV-atrial junction; the  
163 inferior right GP at the inferior-posterior LA, below the right inferior PV.<sup>15,19</sup> The superior left  
164 GP is situated near the junction of the left superior PV, left atrium (LA) and left pulmonary  
165 artery; the inferior left GP at the inferior-posterior LA below the left inferior PV.

## 166 **Outcome Measures**

167       Continuous telemetry monitoring and 7-day Holter monitoring ensued after surgery.  
168 Continuous heart rate variability (HRV) was measured for 7 days following surgery. If AF  $\geq$ 30  
169 seconds was detected by any of the three modalities, it was considered a POAF event: (1) routine  
170 12-lead ECG, (2) continuous telemetry monitoring with full-disclosure until discharge and (3) 7-  
171 day Holter monitoring equipped with an automated algorithm for detection of AF onset and  
172 duration as well as PACs and nonsustained atrial tachycardia as previously described (Yueguang  
173 Medical Technologies, Shanghai, China).<sup>19</sup> POAF events were adjudicated by physicians who  
174 were blinded to randomization. AF burden was defined as the sum of the duration of all episodes  
175 of AF during the 7-day period after surgery. The standard practice to treat POAF in the study  
176 center was to initiate amiodarone therapy after AF sustained  $\geq$  30 minutes or AF caused  
177 hemodynamic concerns. In the presence of myocardial ischemia or hemodynamic compromise,  
178 POAF was treated with cardioversion or intravenous esmolol infusion, in addition to amiodarone  
179 therapy. Inflammatory markers including hsCRP and IL-6 were measured on postoperative day 1  
180 and 3.

## 181 **Surgical specimen acquisition and immunohistochemistry**

182       After midterm analysis, to better understand the mechanisms underlying the contradictory  
183 effect of Ca<sup>2+</sup>-mediated autonomic denervation, 113 consecutive patients referred for CABG or  
184 MV surgery were screened. Forty patients meet the inclusion criteria of the CAPF-AF or CAP-  
185 AF2 trial (CABG, n=20; MV surgery, n=20) gave consent to allow investigators to take tissue

186 samples (average  $0.5 \times 0.5 \text{ cm}^2$ ) in the anterior right GP and adjacent myocardium (**Online**  
187 **Table**). The samples were divided into two parts. One part of the samples was fixed in 4%  
188 paraformaldehyde for 4 hours and embedded in paraffin; sections were performed longitudinally  
189 and cut every 5  $\mu\text{m}$ . The other part was frozen at  $-80^\circ\text{C}$  for subsequent molecular biological  
190 assays.

### 191 **Immunohistochemistry studies**

192 Immunohistochemistry of tyrosine hydroxylase (TH) and choline acetyltransferase (ChAT)  
193 was performed as previously describe.<sup>20</sup> Image analysis of nerve density and  
194 immunohistochemistry staining was detected via ImageJ (Rawak Software Inc., Stuttgart,  
195 Germany). Quantitative analysis of the TH and ChAT expression in myocardial and ARGP  
196 samples was determined by ELISA and Western blot as described before.<sup>20</sup>

### 197 **Statistical Analysis**

198 All analyses were based on the intention-to-treat principle including all patients who were  
199 randomized. For the primary outcome, Kaplan-Meier survival curves were used to describe the  
200 time-dependent incidence of POAF of both groups, the difference of which was compared by the  
201 log-rank test. Secondary outcomes were evaluated by Mann-Whitney U test, Chi-square test or  
202 Fisher's exact test. Data were reported as medians and quartiles (1st, 3rd quartile) for  
203 quantitative data and as numbers for qualitative data. For the heart rate variability (HRV) data  
204 requiring repeated measures, generalized estimating equations were used to test possible  
205 differences in HRV, assuming treatment and time since surgery as fixed factors, with marginal  
206 distribution and a first-order autoregressive correlation matrix to test the main and interaction  
207 effects. All analyses were conducted using the SPSS software (version 24.0) and R software  
208 version 4.1.3. All reported *P* values are two-sided; significant level is 0.05. *P* values and 95%  
209 confidence intervals presented in this report have not been adjusted for multiplicity; therefore,  
210 inferences drawn from these statistics should be interpreted with caution.

211

## 212 **RESULTS**

213           Between November 1, 2020 and March 29, 2022, 884 patients were referred to the  
214 General Hospital of Northern Theater Command for surgery to treat severe MR. A total of 160  
215 patients, who met the inclusion criteria and gave consents, were randomized to the CaCl<sub>2</sub> group  
216 (N=78) and NaCl group (N=82) before the midterm analysis (**Figure 1A**). Baseline  
217 characteristics were not different between the two groups (**Table 1**). Three of 78 patients in the  
218 CaCl<sub>2</sub> group and 2 of 82 patients in the NaCl group had paroxysmal AF based on history and 7-  
219 day Holter monitoring before surgery.

220           No patient received other pharmacological prophylaxis for POAF. All patients underwent  
221 successful surgeries for MV replacement or repair as previously described.<sup>21</sup> Thirty-six and 45  
222 patients underwent MV repair in the CaCl<sub>2</sub> group and NaCl group, respectively. The rest of the  
223 patients received MV replacement. Under direct vision, 2 mL of CaCl<sub>2</sub> or NaCl was injected into  
224 each of the 4 major atrial GP in all 160 patients as described previously.<sup>19</sup> Injection of 4 GP took  
225 approximately 10 minutes. CaCl<sub>2</sub> solution leak was quickly removed by suction to prevent  
226 possible injury to the surrounding tissue. After injection, the pericardial space was irrigated with  
227 saline before closure.

### 228 **Primary Outcome:**

229           Midterm analysis revealed that the POAF incidence was higher in the CaCl<sub>2</sub> group  
230 (55.13%) than that in the NaCl group (37.80%; see results below). The research oversight  
231 committee determined that CaCl<sub>2</sub> injection caused harm and terminated the trial. All the analyses  
232 therefore only included the 160 patients enrolled prior to the midterm analysis (78 and 82  
233 patients in the CaCl<sub>2</sub> and NaCl group, respectively). All 160 patients stayed in the hospital for  $\geq 7$   
234 days; there was no missing data. POAF occurred during the first 7 days after surgery in 31 of 82

235 patients (37.80%) in the NaCl group and 43 of 78 patients (55.13%) in the CaCl<sub>2</sub> group (95%  
236 confidence interval of difference: 1.01%-32.48%,  $P= 0.028$ ) (**Figure 1B**). The Kaplan-Meier  
237 curve also illustrates separation of the two curves on postoperative day 3 when the occurrence of  
238 POAF typically reaches its peak (**Figure 1C**). The median of the first episode of POAF occurred  
239 37.3 (28.1, 48.9) hours after surgery in the NaCl group and 41.5 hours (33.0, 56.9) in the CaCl<sub>2</sub>  
240 group ( $P=0.132$ ). All patients with AF received subcutaneous enoxaparin injection until  
241 discharge.

### 242 **Secondary Outcomes and AF-related measurements**

243 The median length of hospitalization and ICU stay were not different between the two  
244 groups (**Table 2**). When POAF occurred, more patients in the CaCl<sub>2</sub> group were hospitalized >7  
245 days after surgery (69.8% vs. 45.2%,  $P=0.033$ ). Patients in the CaCl<sub>2</sub> group had more episodes of  
246 POAF ( $p=0.007$ ) but with similar AF burden. The average ventricular rate in POAF as well as  
247 the number of patients with POAF>24 hours or >48 hours were not different between the two  
248 groups, either. More patients in the CaCl<sub>2</sub> group required amiodarone to treat POAF, which was  
249 determined by clinicians when POAF lasted longer than 30 minutes. Plasma levels of hs-CRP  
250 and IL-6 on postoperative day 1 and 3 were not different between the two groups. Two patients  
251 in each group required cardioversion for hemodynamic compromise. The time-domain  
252 measurements as well as the frequency domain measurements of HRV such as low frequency  
253 (LF) power, high frequency (HF) power and the LF/HF ratio were not different between the two  
254 groups (**Online Figure 1**). The frequency of PACs, couplets and nonsustained atrial tachycardia  
255 was not different between the two groups on each postoperative day (**Online Figure 2**) as well.

### 256 **Adverse effects and complications**

257 To prevent adverse effects such as significant bradycardia (heart rate <40 bpm) as  
258 described in the CAP-AF trial, CaCl<sub>2</sub> and NaCl were slowly injected into each GP to avoid  
259 pressure buildup inside the GP. No significant bradycardia (<40 bpm) was noticed in any patient.

260 Surgery duration (beginning of sternotomy to completion of wound closure) and peri-operative  
261 mortality and morbidity were not different between the two groups (**Table 2**).

### 262 **Comparison of POAF initiation between the CAP-AF and CAP-AF2 trial**

263 To understand the mechanism(s) responsible for the contradictory effect of  $\text{Ca}^{2+}$ -  
264 mediated autonomic denervation on POAF, we compared the pattern of POAF initiation that was  
265 adjudicated as POAF in the CAP-AF and CAP-AF2 trials. In the CAP-AF2 trial, POAF initiation  
266 was immediately preceded by frequent atrial bigeminy, couplets or nonsustained AT (NSAT,  $\geq 3$   
267 beats) in 33/43 (76.7%; **Figure 2A**) and 9/31 patients (29.0%) in the  $\text{CaCl}_2$  and NaCl group,  
268 respectively ( $P < 0.001$ ). The most common type of POAF initiation in the NaCl group was sinus  
269 rhythm with a single PAC (16/31 patients, 51.6%; **Figure 2B**), which only occurred in 6/43  
270 patients (14.0%) in the  $\text{CaCl}_2$  group ( $P < 0.001$ ). On the contrary, in the CAP-AF trial, POAF  
271 initiation was preceded by frequent atrial bigeminy, couplets or NSAT in 11/15 patients (73.3%)  
272 and 22/36 patients (61.1%) in the  $\text{CaCl}_2$  and NaCl group, respectively ( $P = 0.405$ ). The second  
273 most common initiation pattern was sinus rhythm with a single PAC that occurred in 3/15  
274 (20.0%) and 12/36 (33.3%) patients in the  $\text{CaCl}_2$  and NaCl group, respectively ( $P = 0.341$ ).

### 275 **Immunohistochemical staining of anterior right GP and adjacent atrial myocardium**

276 Parasympathetic and sympathetic neural elements were marked by ChAT and TH  
277 staining, respectively. In the 40 patients not in the CAP-AF or CAP-AF2 trial (n=20 for CABG  
278 and n=20 MR surgery), the percentage of area in the anterior right GP stained positive for TH  
279 was significantly higher in the CABG group but that stained positive for ChAT was higher in the  
280 MV surgery group (**Figure 3A-C**). The ratio of TH/ChAT was therefore significantly higher in  
281 the CABG group. When quantitative analysis of TH and ChAT expressing nerves in the atrial  
282 myocardium adjacent to the ARGP was performed, similar results also hold true for nerve  
283 density (**Figure 3D-F**) as well as protein expression assessed by ELISA (**Figure 3G-I**) and

284 Western blot (**Online Figure 3**). The extent of fibrosis in the atrial myocardium adjacent to the  
285 anterior right GP was not different between the two groups (**Online Figure 4**).

286

## 287 **DISCUSSION**

288 The main finding of the CAP-AF2 trial is that  $\text{Ca}^{2+}$ -mediated autonomic denervation  
289 unexpectedly increased the incidence of POAF in patients with MR without persistent AF,  
290 contradictory to the results of the CAP-AF trial that only recruited patients receiving isolated  
291 CABG. In the CAP-AF2 trial, atrial bigeminy, couplets or NSAT immediately preceded the  
292 initiation of POAF in the  $\text{CaCl}_2$  group but not the NaCl group. Immunohistochemistry studies  
293 demonstrated different autonomic substrates between patients with MR and ischemic heart  
294 disease. A lower ratio of TH/ChAT in the anterior right GP and adjacent myocardium in the  
295 former suggests parasympathetic dominance at the tissue level; a higher TH/ChAT ratio in the  
296 latter suggests sympathetic dominance.  $\text{Ca}^{2+}$ -mediated autonomic denervation therefore exerts  
297 contradictory effects on the incidence of POAF on patients receiving MV surgery vs. CABG.

298 Multiple preclinical studies of MR-related AF have demonstrated similar findings.<sup>22-27</sup>  
299 First, the atrial effective period was prolonged with significant heterogeneity. Second, moderate  
300 but heterogeneous interstitial fibrosis existed. Third, atrial conduction velocity was reduced and  
301 often heterogeneous. Fourth, inflammatory cell infiltration of atrial myocardium was observed.  
302 Fifth, malfunction of major metabolic pathways occurred in patients with MR and was further  
303 augmented by  $\beta$ -adrenergic stimulation. Improvement of metabolic derangement mitigated AF.  
304 Although spontaneous AF was rarely reported by these studies, AF could easily be induced by  
305 electrical stimulation, indicating that in the presence of appropriate triggers, AF can be initiated  
306 and maintained by the aforementioned AF substrates. In the present study, patients with  
307 persistent AF were excluded. The study population therefore represents one in which MR was

308 severe enough that already created a substrate for AF but without appropriate triggers to initiate  
309 AF. Parasympathetic dominance at the tissue level may be protective in patients with severe MR.  
310 Disturbance of the cardiac autonomic balance by  $\text{Ca}^{++}$ -mediate autonomic denervation provided  
311 the triggers to initiate POAF as illustrated in **Figure 2A**.

312 In patients with paroxysmal AF without significant structural heart diseases, AF episodes  
313 are commonly preceded by co-activation of the sympathetic and parasympathetic nervous  
314 systems.<sup>10,12,28</sup> However, exaggerated sympathetic activity is the hallmark of AF initiation. In the  
315 majority of patients including those with structural heart diseases, AF episodes are usually  
316 preceded by an increased low-frequency component of HRV, a marker of sympathetic  
317 hyperactivity.<sup>28</sup> Preclinical studies on ambulatory animals also indicated that paroxysmal AF and  
318 AT were invariably preceded by activation of the intrinsic cardiac ANS evidenced by rapid  
319 discharges recorded from the GP and ligament of Marshall.<sup>11,29</sup> Although the paroxysmal AF or  
320 AT episodes were also accompanied by co-activation of the extrinsic cardiac ANS, such as  
321 vagus nerve and stellate ganglion, 20-25% of the episodes of paroxysmal AT or AF were not  
322 preceded by activation of the vagus nerve or stellate ganglion, indicating that the intrinsic cardiac  
323 ANS (e.g. GP) plays an indispensable role in the initiation of paroxysmal AF or AT. Moreover,  
324 PACs were typically preceded by a surge of sympathetic nerve activity; most of the paroxysmal  
325 AF or AT episodes followed a larger and more sustained surge of sympathetic nerve activity.<sup>11,30</sup>  
326 The average activity of the intrinsic cardiac ANS, evidenced by direct neural recording of GP,  
327 also strongly correlated with the PAC burden in patients after cardiac surgery.<sup>30</sup>

328 In the CAP-AF2 trial, POAF was preceded by frequent atrial bigeminy, couplets or  
329 NSAT in only 9/31 (29.0%) patients in the NaCl group, in contrast to 33/43 (76.7%) patients in  
330 the  $\text{CaCl}_2$  group. That is,  $\text{CaCl}_2$ -mediated autonomic denervation altered the POAF initiation  
331 pattern from sinus rhythm with a single PAC to frequent bigeminy, couplets or NSAT, possibly  
332 resulting from shifting the sympathetic-parasympathetic balance (**Figure 2**). As discussed before,

333 PACs and paroxysmal AT are often preceded by a surge of sympathetic nerve activity.  
334 Immunohistochemistry data revealed parasympathetic dominance at the tissue level (both GP  
335 and atrial myocardium) in patients receiving MV surgery.  $Ca^{2+}$ -mediated autonomic denervation  
336 likely injured more parasympathetic than sympathetic neural elements, which tipped the balance  
337 toward sympathetic dominance. As a result, frequent atrial bigeminy, couplets or NSAT  
338 occurred, eventually initiating POAF. Of note, in the CAP-AF trial,  $Ca^{2+}$ -mediated autonomic  
339 denervation suppressed PACs and NSAT but did not affect the initiation pattern of POAF. We  
340 hypothesize that a higher sympathetic state is also critical in POAF initiation in patients  
341 undergoing CABG.  $Ca^{2+}$ -mediated autonomic denervation mitigated higher tissue sympathetic  
342 activity, evidence by less frequent complex PACs and NSAT. Additionally, HRV showed  
343 diminished HF and LF components but preserved LF/HF ratio,<sup>19</sup> suggesting that the sympathetic-  
344 parasympathetic balance was not perturbed by autonomic denervation thereby not altering the  
345 initiation pattern of POAF. Therefore, for patients in the  $CaCl_2$  group of the CAP-AF trial, if  
346 autonomic denervation failed to overcome the higher sympathetic activity, POAF was triggered  
347 by similar mechanisms as seen in the NaCl group. Based on the contradictory results in the CAP-  
348 AF and CAP-AF2 trials, perturbation of the autonomic balance can be beneficial or harmful,  
349 depending on the underlying substrate.

350 An important lesson learned from the two CAP-AF trials is that autonomic remodeling  
351 and perhaps other remodeling processes may vary greatly among different cardiovascular  
352 diseases, leading to differential effects on POAF when cardiac ANS is perturbed. If the CAP-  
353 AF2 trial had recruited both MV surgery and CABG populations, the results might have been  
354 neutral; the harm to the MV surgery population would have not been exposed. Future studies on  
355 the pathogenesis or therapies of AF, not limited to POAF, may need to focus on a relatively  
356 homogeneous population and avoid a study population including multiple cardiovascular  
357 diseases. For example, the AFACT<sup>31</sup> trial randomized patients to surgical PVI vs. surgical



358 PVI+GP ablation and reported no benefit conferred by GP ablation, contradictory to the  
359 beneficial effects of GP ablation reported by the largest randomized clinical trial (catheter PVI  
360 vs. PVI+GP ablation) that only recruited patients with paroxysmal AF without prior ablation.<sup>16</sup>  
361 Notably, in the AFACT trial, 59% patients had persistent AF, 43% patients had severely  
362 enlarged left atrium (LA volume index>40 mL/M<sup>2</sup>), and nearly 25% had prior catheter ablation.  
363 The conflicting results from the aforementioned two trials may stem from two distinct study  
364 populations. Two recently published trials further exemplified this viewpoint. By injecting  
365 botulinum toxin into the major atrial GP as a means of autonomic denervation, reduction of the  
366 incidence of POAF was reported in one randomized clinical trial on patients receiving CABG but  
367 a neutral effect was reported by the other trial recruiting patients undergoing CABG and/or valve  
368 surgery.<sup>32, 33</sup>

### 369 **Study Limitation**

370 First, we did not directly record the neural activity of the GP; the activity of the intrinsic  
371 cardiac ANS was therefore deduced from expression of TH and ChAT in the anterior right GP  
372 and adjacent myocardium. In addition, the postoperative HRV was inconclusive likely due to a  
373 smaller-than-expected sample size resulting from premature termination of the trial. The  
374 interpretation that higher sympathetic activity preceded POAF was therefore based on published  
375 pre-clinical and clinical studies. Second, we do not have immunohistochemical data on normal  
376 controls to compare tissue autonomic innervation among normal controls, patients with MR and  
377 patients with ischemic heart disease. Therefore, sympathetic and parasympathetic dominance  
378 described in this study only represents the comparison between the MR and CABG populations.  
379 Third, for logistical reasons, only the anterior right GP and adjacent myocardium were sampled.  
380 Tissue autonomic innervation and fibrosis may not be generalized to the entire atrial neural  
381 network and myocardium. Fourth, only five of 160 patients were found to have paroxysmal AF  
382 based on history and 7-day Holter monitoring prior to surgery. The prevalence of paroxysmal AF

383 is probably underestimated. We presume that under-diagnosis of paroxysmal AF would have  
384 been evenly distributed by randomization and will not affect the outcome assessment.

385

## 386 **CONCLUSIONS**

387 Unlike patients undergoing CABG, autonomic denervation increased the risk of POAF in  
388 patients receiving MV surgery, indicating distinct substrates for POAF in different  
389 cardiovascular diseases. This observation may explain conflicting results from published POAF  
390 trials that recruited patients undergoing CABG and valvular surgery. While autonomic  
391 denervation has emerged as a novel therapy to treat various cardiovascular diseases, it should  
392 only be performed with evidence supported by randomized clinical trials.

393

394

395 **Source of Funding:** LiaoNing Revitalization Talents Program: XLYC2001001 (Dr. Huishan  
396 Wang)

397 **Disclosure:** No author has conflict of interest.

398

399

400 **REFERENCES:**

- 401 1. Dobrev D, Aguilar M, Heijman J, Guichard JB, Nattel S. Postoperative atrial fibrillation:  
402 mechanisms, manifestations and management. *Nat Rev Cardiol* 2019;16:417-36.
- 403 2. Crystal E, Connolly SJ, Sleik K, Ginger TJ, Yusuf S. Interventions on prevention of  
404 postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. *Circulation*  
405 2002;106:75-80.
- 406 3. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial  
407 fibrillation developed in collaboration with EACTS. *Eur Heart J* 2016;37:2893-962.
- 408 4. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014  
409 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of  
410 the American College of Cardiology/American Heart Association Task Force on Clinical  
411 Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol* 2019;74:104-32.
- 412 5. Mitchell LB, Exner DV, Wyse DG, et al. Prophylactic Oral Amiodarone for the Prevention of  
413 Arrhythmias that Begin Early After Revascularization, Valve Replacement, or Repair:  
414 PAPABEAR: a randomized controlled trial. *Jama* 2005;294:3093-100.
- 415 6. Ardell JL, Andresen MC, Armour JA, et al. Translational neurocardiology: preclinical models  
416 and cardioneural integrative aspects. *J Physiol* 2016;594:3877-909.
- 417 7. Pauza DH, Skripka V, Pauziene N, Stropus R. Morphology, distribution, and variability of the  
418 epicardiac neural ganglionated subplexuses in the human heart. *Anat Rec* 2000;259:353-82.
- 419 8. Ardell JL, Armour JA. Neurocardiology: Structure-Based Function. *Compr Physiol*  
420 2016;6:1635-53.
- 421 9. Hou Y, Scherlag BJ, Lin J, et al. Ganglionated plexi modulate extrinsic cardiac autonomic  
422 nerve input: effects on sinus rate, atrioventricular conduction, refractoriness, and inducibility of  
423 atrial fibrillation. *J Am Coll Cardiol* 2007;50:61-8.

- 424 10. Lombardi F, Tarricone D, Tundo F, Colombo F, Belletti S, Fiorentini C. Autonomic nervous  
425 system and paroxysmal atrial fibrillation: a study based on the analysis of RR interval changes  
426 before, during and after paroxysmal atrial fibrillation. *Eur Heart J* 2004;25:1242-8.
- 427 11. Tan AY, Zhou S, Ogawa M, et al. Neural mechanisms of paroxysmal atrial fibrillation and  
428 paroxysmal atrial tachycardia in ambulatory canines. *Circulation* 2008;118:916-25.
- 429 12. Bettoni M, Zimmermann M. Autonomic tone variations before the onset of paroxysmal atrial  
430 fibrillation. *Circulation* 2002;105:2753-9.
- 431 13. Patterson E, Po SS, Scherlag BJ, Lazzara R. Triggered firing in pulmonary veins initiated by  
432 in vitro autonomic nerve stimulation. *Heart Rhythm* 2005;2:624-31.
- 433 14. Patterson E, Lazzara R, Szabo B, et al. Sodium-calcium exchange initiated by the Ca<sup>2+</sup>  
434 transient: an arrhythmia trigger within pulmonary veins. *J Am Coll Cardiol* 2006;47:1196-206.
- 435 15. Po SS, Nakagawa H, Jackman WM. Localization of left atrial ganglionated plexi in patients  
436 with atrial fibrillation. *J Cardiovasc Electrophysiol* 2009;20:1186-9.
- 437 16. Katritsis DG, Pokushalov E, Romanov A, et al. Autonomic denervation added to pulmonary  
438 vein isolation for paroxysmal atrial fibrillation: a randomized clinical trial. *J Am Coll Cardiol*  
439 2013;62:2318-25.
- 440 17. Peunova N, Enikolopov G. Amplification of calcium-induced gene transcription by nitric  
441 oxide in neuronal cells. *Nature* 1993;364:450-3.
- 442 18. Arundine M, Tymianski M. Molecular mechanisms of calcium-dependent neurodegeneration  
443 in excitotoxicity. *Cell Calcium* 2003;34:325-37.
- 444 19. Wang H, Zhang Y, Xin F, et al. Calcium-Induced Autonomic Denervation in Patients With  
445 Post-Operative Atrial Fibrillation. *J Am Coll Cardiol* 2021;77:57-67.
- 446 20. Zhao J, Zhang Y, Yin Z, et al. Impact of proinflammatory epicardial adipose tissue and  
447 differentially enhanced autonomic remodeling on human atrial fibrillation. *J Thorac Cardiovasc*  
448 *Surg* 2022.

- 449 21. Wang H, Han J, Wang Z, et al. A prospective randomized trial of the cut-and-sew Maze  
450 procedure in patients undergoing surgery for rheumatic mitral valve disease. *J Thorac*  
451 *Cardiovasc Surg* 2018;155:608-17.
- 452 22. Everett TH 4th, Verheule S, Wilson EE, Foreman S, Olgin JE. Left atrial dilatation resulting  
453 from chronic mitral regurgitation decreases spatiotemporal organization of atrial fibrillation in  
454 left atrium. *Am J Physiol Heart Circ Physiol*. 2004 Jun;286(6):H2452-60.
- 455 23. Verheule S, Wilson E, Everett T 4th, Shanbhag S, Golden C, Olgin J. Alterations in atrial  
456 electrophysiology and tissue structure in a canine model of chronic atrial dilatation due to mitral  
457 regurgitation. *Circulation*. 2003 May 27;107(20):2615-22.
- 458 24. Everett TH 4th, Wilson EE, Verheule S, Guerra JM, Foreman S, Olgin JE. Structural atrial  
459 remodeling alters the substrate and spatiotemporal organization of atrial fibrillation: a  
460 comparison in canine models of structural and electrical atrial remodeling.  
461 *Am J Physiol Heart Circ Physiol*. 2006 Dec;291(6):H2911-23.
- 462 25. Tang M, Zhang S, Sun Q, Huang C. Alterations in Electrophysiology and Tissue Structure of  
463 the Left Atrial Posterior Wall in a Canine Model of Atrial Fibrillation Caused by Chronic Atrial  
464 Dilatation. *Circ J* 2007;71:1636-1642.
- 465 26. Monti LD, Lucotti PC, Setola E et al. Effects of chronic elevation of atrial natriuretic peptide  
466 and free fatty acid levels in the induction of type 2 diabetes mellitus and insulin resistance in  
467 patients with mitral valve disease. *Nutr Metab Cardiovasc Dis*. 2012 Jan;22(1):58-65.
- 468 27. Oikawa S, Kai Y, Mano A, et al. Non-neuronal cardiac acetylcholine system playing  
469 indispensable roles in cardiac homeostasis confers resiliency to the heart. *J Physiol Sci*. 2021 Jan  
470 18;71(1):2.

- 471 28. Carnagarin R, Kiuchi MG, Ho JK, Matthews VB, Schlaich MP. Sympathetic Nervous  
472 System Activation and Its Modulation: Role in Atrial Fibrillation. *Front Neurosci* 2018;12:1058.
- 473 29. Choi EK, Shen MJ, Han S, et al. Intrinsic cardiac nerve activity and paroxysmal atrial  
474 tachyarrhythmia in ambulatory dogs. *Circulation* 2010;121:2615-23.
- 475 30. Shen MJ, Coffey AC, Straka S, et al. Simultaneous recordings of intrinsic cardiac nerve  
476 activity and skin sympathetic nerve activity from human patients during the postoperative period.  
477 *Heart Rhythm* 2017;14:1587-93.
- 478 31. Driessen AHG, Berger WR, Krul APJ, van den Berg NWE, Neefs J, Piersma FR, Yin  
479 DRPPCP<sup>2</sup>, de Jong JSSG<sup>3</sup>, van Boven WP, de Groot JR. Ganglion Plexus Ablation in Advanced  
480 Atrial Fibrillation: The AFACT Study. *J Am Coll Cardiol*. 2016 Sep 13;68(11):1155-1165.
- 481 32. Pokushalov E, Kozlov B, Romanov A, et al. Botulinum toxin injection in epicardial fat pads  
482 can prevent recurrences of atrial fibrillation after cardiac surgery: results of a randomized pilot  
483 study. *J Am Coll Cardiol* 2014;64:628-9.
- 484 33. Waldron NH, Cooter M, Haney JC, et al. Temporary autonomic modulation with botulinum  
485 toxin type A to reduce atrial fibrillation after cardiac surgery. *Heart Rhythm* 2019;16:178-84.  
486

487 **FIGURE LEGENDS**

488 **Figure 1. Trial design and primary outcome. A. Flow diagram of trial design.** A total of 884  
489 patients were screened. Up to the midterm analysis, 160 patients consented to participate.  
490 Participants were 1:1 randomized to CaCl<sub>2</sub> injection and NaCl injection. **B. Cumulative**  
491 incidence of POAF over 7 days after surgery. **C. Kaplan-Meier curve of POAF.** HR: hazard  
492 ratio. CI: 95% confidence interval.

493  
494 **Figure 2. The most common pattern of POAF initiation in the CAP-AF2 trial. A.** POAF was  
495 preceded by frequent atrial bigeminy, couplets or nonsustained AT in the CaCl<sub>2</sub> group **B. A**  
496 single PAC (red arrow) initiated POAF in the NaCl group.

497  
498 **Figure 3. Tissue autonomic innervation.** Tissue samples obtained from patients undergoing  
499 coronary artery bypass surgery (CABG, n=20) or mitral valve surgery (MVS, n=20) for mitral  
500 regurgitation. **A-C.** Percentage of the area in the anterior right ganglionated plexi stained  
501 positive for choline acetyltransferase (ChAT; **A**) or tyrosine hydroxylase (TH, **B**) as well as the  
502 TH/ChAT ratio (**C**). **D-F.** ChAT staining, TH staining and TH/ChAT ratio of autonomic nerves.  
503 **G-I.** Quantitative analysis by ELISA of TH and ChAT expression. **D-I.** Tissue samples obtained  
504 from atrial myocardium adjacent to the anterior right ganglionated plexi. GP. \*:  $p<0.05$ ; \*\*:  
505  $p<0.01$ ; \*\*\*:  $p<0.001$ .

506

507  
508

**Table 1. Demographic and Clinical Characteristics at Baseline**

	<b>CaCl<sub>2</sub> (n=78)</b>	<b>NaCl (n=82)</b>	<b>P</b>
Age, yrs	60 (56, 63)	61 (53.25, 66)	0.652
Female, n (%) *	32 (41.03)	38 (46.34)	0.498
Hypertension, n (%) *	33 (42.31)	25 (30.49)	0.120
Diabetes, n (%) *	9 (11.54)	5 (6.1)	0.223
paroxysmal AF, n (%) *	3 (3.85)	2 (2.44)	0.955
CHA <sub>2</sub> DS <sub>2</sub> -VASc score	1 (0,2)	1 (1,2)	0.235
CAD, n (%) *	18 (23.08)	12 (14.63)	0.171
EF, %	57 (55, 60)	58 (56, 60)	0.167
FS, %	30 (28, 32)	30 (29, 32)	0.093
Left atrium, mm	44 (40, 48)	42 (38, 46.25)	0.084
On β-blocker, n (%)	31 (39.7%)	28 (34.2%)	0.463
Average HR, beats/min	74 (69.5, 80)	75 (70, 82)	0.323
Highest HR, beats/min	117 (109, 127)	118 (110, 130)	0.227
Lowest HR, beats/min	51 (48, 57)	54 (49, 59)	0.069
hsCRP, mg/l	0.25 (0.25, 3.1)	0.61 (0.25,1.75)	0.788
IL6, pg/l	3.08 (1.87, 6.68)	2.73 (1.85, 4.88)	0.838
BNP, pg/l	461.6 (107.9, 1622)	223.2 (107.7, 764.32)	0.850
ALT, U/l	19.7 (14.32, 26.65)	17.2 (13.51, 27.56)	0.390
AST, U/l	19.76 (15.35, 26.24)	19.04 (16.74, 26.51)	0.738
Creatinine, mmol/l	74.11 (62.61, 83.5)	67.98 (60.83, 81.46)	0.348
Heart rate variability			
pNN50, %	3.35(1.42, 9)	3.25(0.9, 9.75)	0.391
rMSSD, ms	19.5(15.83, 29.4)	19.85(13.83, 31.1)	0.941
SDNN, ms	55.2 (45.7, 64.15)	55.3 (42.1, 66.22)	0.927
Premature atrial beats			
Single, %	0.07 (0.02, 0.27)	0.1 (0.02, 0.27)	0.819
Couplets, 10 <sup>-2</sup> .%	0.23 (0.04, 0.87)	0.22 (0.05, 0.86)	0.988
NSAT, 10 <sup>-2</sup> .%	0.11 (0.03, 0.47)	0.19 (0.03, 0.62)	0.380

509 Values are median (1st, 3rd quartile), or n (percentage). AF= atrial fibrillation; ALT = alanine  
510 transaminase; AST = aspartate transaminase; BNP = brain natriuretic peptide; CAD: coronary  
511 artery disease; EF = ejection fraction; FS = Fraction shortening; COPD = chronic obstructive  
512 pulmonary disease; hsCRP = high-sensitivity C-reaction protein; IL-6 = interleukin-6; MI =  
513 history of myocardial infarction; pNN50 =percentage of RR intervals that differ by >50 ms;  
514 rMSSD =root-mean-square of successive RR interval difference; SDNN = SD of normal-to-  
515 normal interval; NSAT=non-sustained atrial tachyarrhythmia. \*: Calculated by chi-square test.  
516 Others: calculated by Mann-Whitney *U* test.

517



518


**Table 2. Secondary outcomes and peri-operative conditions**

	CaCl <sub>2</sub> (n=78)	NaCl (n=82)	p
ICU stay, hours	24 (21, 37.25)	23 (20, 37.75)	0.799
Hospitalization, days	8 (7, 9)	8 (7, 9)	0.317
Hospitalization > 7 days, n (%) *	30 (69.8)	14 (45.2)	<b>0.033</b>
AF burden, %	2.01 (0, 25.07)	0 (0, 10.24)	0.066
Number of AF episodes in patient	1 (0, 4)	0 (0, 1)	<b>0.007</b>
Average ventricular rate in AF	103 (87, 127)	108 (94, 125)	0.349
Patients with AF >48h, n (%) *	11 (14.10)	10 (12.20)	0.721
Patients with AF >24h, n (%) *	19 (24.36)	12 (14.63)	0.120
<b>Inflammatory markers</b>			
hs-CRP (POD1), mg/L	41.78 (16.83, 60.02)	37.16 (23.57, 68.7)	0.444
IL6 (POD1), pg/L	89.60 (63.90, 131.83)	95.25 (58.62, 130.35)	0.661
Hs-CRP (POD3), mg/L	119.47 (83.04, 169.62)	122.62 (82.51, 178.97)	0.500
IL6 (POD3), pg/L	62.94 (41.39, 99.46)	71.72 (39.13, 103.67)	0.965
Amiodarone, n (%) *			<b>0.039</b>
0	63 (80.77)	75 (91.46)	
0-2500 mg	10 (12.82)	7 (8.54)	
>2500 mg	5 (6.41)	0 (0)	
Esmolol, n (%) *			0.873
0	53 (67.95)	55 (67.07)	
0-600 mg	5 (6.41)	7 (8.54)	
>600 mg	20 (25.64)	20 (24.39)	
Cardioversion, n (%) †	2 (2.56)	2 (2.44)	>0.999
Major surgery time, min	111 (90, 137)	116 (91, 145)	0.565
<b>Surgery type, n (%) *</b>			
MV repair	36 (46.16)	45 (54.88)	0.270
MV replacement	42 (53.85)	37 (45.12)	
<b>MV replacement, n (%) *</b>			
Mechanical valve	28 (66.67)	26 (70.27)	0.731
Tissue valve	14 (33.33)	11 (29.73)	
Death, n (%)	0	0	-
Post-operative EF, %	56 (53, 58)	57 (55, 59)	0.222
Troponin-T, ng/L	380(260.25, 559.75)	333.5(243.75, 490.25)	0.131
Poor wound healing, n (%)	0	0	-
Procalcitonin (POD3), ng/mL	0.14(0.11, 0.17)	0.13(0.10, 0.15)	0.083
Pleural effusion, n (%) †	1 (1.28)	4 (4.88)	0.368
On ventilator >96 h, n (%) †	1 (1.28)	0	0.487
Average heart rate (bpm)	85 (79, 91)	85 (76, 93)	0.768
Renal dysfunction, n (%) †	1 (1.28)	0	0.487
Post-operative myocardial infarction, %	0	0	-
Stroke, %	0	0	-

519 Values are median (1st, 3rd quartile) or n (percentage). POD: postoperative day. All  
 520 abbreviations identical to Table 1. \*Calculated by chi-square test. †Calculated by Fisher exact  
 521 test. Others: calculated by Mann-Whitney *U* test.  
 522

523 **Figure 1. Trial design and primary outcome. A. Flow diagram of trial design.** A total of 884  
524 patients were screened. Up to the midterm analysis, 160 patients consented to participate.  
525 Participants were 1:1 randomized to CaCl<sub>2</sub> injection and NaCl injection. **B.** Cumulative  
526 incidence of POAF over 7 days after surgery. **C.** Kaplan-Meier curve of POAF. HR: hazard  
527 ratio. CI: 95% confidence interval.


**Figure 1A.**



528


529

**Figure 1B.**



530

**Figure 1C.**



Number at risk

NaCl	0	4	23	29	31	31	31	31
CaCl <sub>2</sub>	0	6	26	40	42	43	43	43

531

532

533 **Figure 2. The most common pattern of POAF initiation in the CAP-AF2 trial. A.** POAF was  
534 preceded by frequent atrial bigeminy, couplets or nonsustained AT in the CaCl<sub>2</sub> group **B.** A  
535 single PAC (red arrow) initiated POAF in the NaCl group.


## Figure 2A.



536

POAF

## Figure 2B.




POAF

537

538

539 **Figure 3. Tissue autonomic innervation.** Tissue samples obtained from patients undergoing  
540 coronary artery bypass surgery (CABG, n=20) or mitral valve surgery (MVS, n=20) for mitral  
541 regurgitation. **A-C.** Percentage of the area in the anterior right ganglionated plexi stained  
542 positive for choline acetyltransferase (ChAT; **A**) or tyrosine hydroxylase (TH, **B**) as well as the  
543 TH/ChAT ratio (**C**). **D-F.** ChAT staining, TH staining and TH/ChAT ratio of autonomic nerves.  
544 **G-I.** Quantitative analysis by ELISA of TH and ChAT expression. **D-I.** Tissue samples obtained  
545 from atrial myocardium adjacent to the anterior right ganglionated plexi. GP. \*:  $p < 0.05$ ; \*\*:  $p < 0.01$ ; \*\*\*:  $p < 0.001$ .

**Figure 3.**



547